Evexta Bio Appoints Dr. Edith A. Perez as Scientific Advisor
Evexta Bio SA, a clinical-stage biotechnology company dedicated to developing innovative therapies in oncology, has announced the exciting appointment of Dr. Edith A. Perez as its new Scientific Advisor. This decision reflects the company’s commitment to enhancing its clinical research capabilities and improving patient outcomes.
Dr. Perez's Impressive Academic Background
Dr. Edith A. Perez boasts an impressive academic history, having earned her B.S. in Biology and M.D. from the University of Puerto Rico. Following her graduation, she sharpened her skills at Loma Linda University Medical Center in California and completed a fellowship in hematology and oncology at the University of California at Davis. Throughout her career, Dr. Perez has made invaluable contributions to cancer research, focusing especially on breast cancer and developing new cancer therapies.
Distinguished Career at Mayo Clinic
Dr. Perez's illustrious career includes more than twenty years at the Mayo Clinic, where she played crucial roles in clinical practice, research, and education. Her work has been influential in shaping the future of oncology, and her achievements at the clinic have earned her the title of Professor Emeritus.
Leadership Roles and Responsibilities
Before joining Evexta Bio, Dr. Perez held significant positions in various organizations. Notably, she was Vice President and Head of U.S. Medical Affairs in Bio-Oncology at Genentech from 2015 to 2018 and then served as Chief Medical Officer of Bolt Biotherapeutics from 2020 to 2024. Her leadership extends to non-profit organizations, including the Puerto Rico Science Technology and Research Trust and Food Allergy Research and Education.
Focused Approach on Drug Development Strategy
As she takes on her role at Evexta Bio, Dr. Perez aims to contribute to the strategic direction of the company's drug development initiatives. Her insights are particularly valuable as Evexta Bio focuses on addressing significant unmet needs in healthcare, particularly for patients suffering from advanced breast cancer.
CEO's Statement
Scott Filosi, CEO of Evexta Bio, expressed his enthusiasm about the appointment, stating, "I am happy to welcome Edith as our Scientific Advisor. We are convinced that her experience will play a vital role in our ongoing clinical research and improvement of patient outcomes."
Innovative Therapeutic Developments at Evexta Bio
Evexta Bio is dedicated to pioneering new therapies in oncology. The company is in the clinical stages of developing two proprietary therapeutic assets with novel mechanisms of action. These include:
Rupitasertib
This optimized S6K inhibitor targets the compensatory AKT feedback loop. It is anticipated to enter phase 2 clinical trials specifically for patients with advanced breast cancer characterized by ESR1 mutations.
EVX020
EVX020 is a distinctive KIF20A kinesin inhibitor that has demonstrated considerable efficacy in both hematological and solid tumor models. Currently, two development strategies are being explored for this agent: as a prodrug and as a component of an antibody-drug conjugate (ADC).
Company Overview and Collaborations
Founded by Truffle Capital, and with the backing of significant shareholders like Merck KGaA, Evexta Bio is well-positioned to lead innovative therapeutic advancements. The company has established partnerships with prominent academic and industry leaders, including CNRS and the Paoli-Calmettes Institute. Supported by a seasoned management team and a dedicated board, Evexta Bio continues to forge paths in the development of life-changing treatments.
Frequently Asked Questions
Who has been appointed as the Scientific Advisor for Evexta Bio?
Dr. Edith A. Perez has been appointed as the Scientific Advisor for Evexta Bio.
What is the educational background of Dr. Edith A. Perez?
Dr. Perez holds a B.S. in Biology and an M.D. from the University of Puerto Rico and has extensive training in oncology.
What are the main areas of focus for Evexta Bio?
Evexta Bio focuses on developing innovative therapies for oncology, specifically targeting advanced breast cancer.
What notable positions has Dr. Perez held?
Dr. Perez has served as Vice President at Genentech and Chief Medical Officer at Bolt Biotherapeutics.
What therapeutic assets is Evexta Bio currently developing?
Evexta Bio is developing Rupitasertib and EVX020, targeting advanced breast cancer and offering innovative approaches to cancer treatment.